MMJ Group Holdings Ltd Stock Market Press Releases and Company Profile
MediPharm Labs Enters Contract with Emerald
MediPharm Labs Enters Contract with Emerald

Perth, Oct 11, 2018 AEST (ABN Newswire) - MMJ PhytoTech Limited (googlechartASX:MMJ) (googlechartMMJJF:OTCMKTS) ("MMJ") is pleased to attach a release from MediPharm Labs Inc ("MediPharm Labs") (TSX-V: LABS) announcing that it has entered into a Cannabis Concentrate Program Agreement with Emerald Health Therapeutics Inc ("Emerald") (googlechartCVE:EMH).

MMJ has CAD$5 million of equity invested in MediPharm Labs with 5.88 million shares (CAD$0.85 cost per share) and 2.94 million warrants (exercisable at CAD$1.20 per share by October 2020).

To view the release, please visit:
http://abnnewswire.net/lnk/F8RY7W5L


About MMJ Group Holdings Ltd

Phytotech Medical ASX:PYL

MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: https://www.mmjphytotech.com.au/investors/

https://plus.google.com/112611716213432048650/posts https://www.youtube.com/channel/UCkDxKKC_fe2TdZfeVSpPVhw abnnewswire.com 


Contact

Investor and Media Enquiries:
Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: info@mmjgh.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 16) (Last 30 Days: 58) (Since Published: 7296)